



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/783,927	02/20/2004	Ronald A. Fleming	Kucera-5001	7276
9629 7590 03/04/2008 MORGAN LEWIS & BOCKIUS LLP 1111 PENNSYLVANIA AVENUE NW WASHINGTON, DC 20004				
EXAMINER				
ANDERSON, JAMES D				
ART UNIT		PAPER NUMBER		
1614				
MAIL DATE		DELIVERY MODE		
03/04/2008		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/783,927

Applicant(s)

FLEMING ET AL.

Examiner

JAMES D. ANDERSON

Art Unit

1614

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 01 November 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-65 is/are pending in the application.
- 4a) Of the above claim(s) 2-6 and 14-64 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1, 7-13 and 65 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/S5108)
Paper No(s)/Mail Date 8 sheets.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____.
- 5) ☐ Notice of Informal Patent Application.
- 6) ☐ Other: _____.

DETAILED ACTION

Claims 1-65 are presented for examination

Election/Restrictions

Applicant's election of Group I (claims 1-13 and 64-65) in the reply filed on 11/1/2007 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Applicant's further election of the compound of Formula I, wherein

R₁ is -NHC(O)Y, where Y is C₂₂ alkyl;

R₂ is -OX, where X is C₂₂ alkyl; and

R₃ is phosphocholine

in the reply filed on 11/1/2007 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Applicant's further election of coronavirus as the virus to be treated in the reply filed on 11/1/2007 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)). A search of the claimed methods uncovered art directed to treating virus infections generally and specifically reciting the treatment of herpes viruses as recited in the instant claims. Accordingly, the treatment of herpes viruses as recited in claims 1 and 9-10 are also under examination.

Claims 2-6 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected species of Formula (I), there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on 11/1/2007 (see above).

Claim 64 is withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected virus, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on 11/1/2007 (see above).

Claims 14-63 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on 11/1/2007 (see above).

Status of the Claims

This is the first Office Action on the merits of the claims. Claims 1-65 are currently pending. Claims 2-6 and 14-64 are withdrawn from further consideration as discussed *supra*.

Accordingly, claims 1, 7-13, and 65 are presently under examination and are the subject of this Office Action.

Priority

The instant application does not claim priority to any prior-filed U.S. or foreign applications. Accordingly, the earliest effective U.S. filing date afforded the instant claims is **2/20/2004**, the filing date of the instant application.

Information Disclosure Statement

Receipt is acknowledged of the Information Disclosure Statement filed 9/14/2007. The Examiner has considered the references cited therein to the extent that each is a proper citation. Please see the attached USPTO Form 1449.

Claim Rejections - 35 USC § 112 (1st Paragraph)

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1, 7-13, and 65 are rejected under 35 U.S.C. § 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a Written Description rejection.

Regarding the requirement for adequate written description of chemical entities, Applicant's attention is directed to the MPEP §2163. In particular, *Regents of the University of California v. Eli Lilly & Co.*, 119 F.3d 1559, 1568 (Fed. Cir. 1997), *cert. denied*, 523 U.S. 1089, 118 S. Ct. 1548 (1998), holds that an adequate written description requires a precise definition, such as by structure, formula, chemical name, or physical properties, "not a mere wish or plain for obtaining the claimed chemical invention." *Eli Lilly*, 119 F.3d at 1566. The Federal Circuit has adopted the standard set forth in the Patent and Trademark Office ("PTO") Guidelines for Examination of Patent Applications under the 35 U.S.C. 112.I "Written Description"

Requirement ("Guidelines"), 66 Fed. Reg. 1099 (Jan. 5, 2001), which state that the written description requirement can be met by "showing that an invention is complete by disclosure of sufficiently detailed, relevant identifying characteristics," including, *inter alia*, "functional characteristics when coupled with a known or disclosed correlation between function and structure..." *Enzo Biochem, Inc. v. Gen-Probe Inc.*, 296 F.3d 316, 1324-25 (Fed. Cir. 2002) (quoting *Guidelines*, 66 Fed. Reg. at 1106 (emphasis added)). Moreover, although *Eli Lilly* and *Enzo* were decided within the factual context of DNA sequences, this does not preclude extending the reasoning of those cases to chemical structures in general. *Univ. of Rochester v. G.D. Searle & Co.*, 249 Supp. 2d 216, 225 (W.D.N.Y. 2003).

In the instant case, the claims recite a genus of compounds of Formula (I) or "prodrug thereof" (e.g., claim 1). There is insufficient written description of the claimed prodrugs of compounds of Formula (I).

Despite the disclosure that "prodrugs" of the claimed compounds of Formula (I) are encompassed by the claims (e.g., claim 1; page 22 of specification), it remains that the specification provides no chemical structures or description of the compounds described as "prodrugs" that may be used within the context of the present invention. It has been held in patent law that a wish or plan for obtaining the invention as claimed does not provide adequate written description of a chemical invention. Rather, a precise definition, such as by structure, formula, chemical name or physical properties or a combination thereof, is required. Please reference, e.g., *Univ. of Rochester v. G.D. Searle & Co.*, 358 F.3d 916, 927, 69 USPQ2d 1886, 1894-95 (Fed. Cir. 2004). In other words, though Applicants may have a plan for how to identify other agents that may be amenable for use in the present invention (such as the claimed

Art Unit: 1614

prodrugs), it remains that at the time of the invention, Applicants had not identified such compounds, and, therefore, did not have written description of the full scope of the genus claimed.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(e) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).


Claims 1, 9-13, and 65 are rejected under 35 U.S.C. 103(a) as being unpatentable over **Kucera *et al.*** (USP No. 5,962,437; Issued Oct. 5, 1999) (cited by Applicants in IDS filed 9/14/2007).

The instant claims recite methods of treating a host infected with a togavirus, a coronavirus (elected), or a herpes virus (also under examination) comprising administering a compound of Formula (I) as recited in claim 1 wherein,

R₁ is -NHC(O)Y, where Y is C₂₂ alkyl;


R₂ is -OX, where X is C₂₂ alkyl; and

R₃ is phosphocholine.



Elected compound of Formula (I)

Kucera *et al.* teach methods of treating viral infections, and in particular HIV-1, hepatitis B virus, and herpes viruses, comprising administering an infection-combating amount of a phospholipid or phospholipid derivative (Abstract). In particular, compounds of Formula (I) are disclosed, wherein R₁ is a C₆ to C₁₈ alkyl group, X is NHCO, R₂ is C₆ to C₁₄ alkyl, Y is O, R₆ is C₂ to C₆ alkyl, and R₃, R₄, and R₅ are methyl or ethyl (col. 2, lines 3-35):



Compounds of Formula I (Kucera *et al.*)

The compounds of Formula (I) disclosed in Kucera *et al.* are taught to attach to the cell membrane and thus are particularly effective against infections caused by membrane-containing or envelope containing viruses (col. 9, lines 42-45), including herpes viruses as instantly claimed (col. 9, line 59). The administration routes recited in instant claim 65 are taught at column 10, lines 14-21.

The cited reference differs from the instant claims in the length of the alkyl chains at R₁ and R₂ in the compounds of Formula (I). For example, the elected compound of Formula (I) has a C₂₂ alkyl chain at R₁ and R₂, whereas the reference limits these substituents to C₆ to C₁₈ alkyl and C₆ to C₁₄ alkyl, respectively.

However, in the absence of a showing of unexpected results commensurate in scope with the claims, it would have been *prima facie* obvious at the time the invention was made to lengthen the alkyl chain length of the R₁ and R₂ substituents in the compounds of Formula (I) as disclosed in Kucera *et al.* Such extending of alkyl chain lengths would have been obvious to one of ordinary skill in the art because members of a homologous series of chemical compounds possess the same principal characteristics which vary gradual from member to member. As such, one skilled in the art would have been imbued with at least a reasonable expectation that compounds of Formula (I) as disclosed in Kucera *et al.* having longer chain lengths would also be effective in treating viral infection such as herpes viral infections as suggested and motivated

Art Unit: 1614

by Kucera *et al.* See *In re NORRIS*, 84 USPQ 458 (C.C.P.A. 1950) wherein the court, citing 31 C.C.P.A. (Patents) 895, 903 and 908; 141 F.2d 122, 127 and 130; and 60 USPQ 544, 548 and 552 (“Hass *et al.*” cases) affirmed that “novel members of a homologous series of chemical compounds must possess some unobvious or unexpected beneficial properties not possessed by a homologous compound disclosed in the prior art.” In the instant case, no unobvious or unexpected beneficial properties of the elected compound of Formula (I) have been proffered.

With respect to the specific herpes viruses recited in claims 10-11, in the absence of a showing of unexpected results commensurate in scope with the claims, it would have been *prima facie* obvious to treat any type of herpes virus infection using the compounds suggested and motivated by Kucera *et al.* because the inventors therein suggest (and even claim) the treatment of “viral infection”, exemplifying the treatment of herpes viruses, with the compounds of Formula (I) disclosed therein. As such, one of ordinary skill in the art would have been motivated to treat any herpes virus type, especially membrane-containing or envelope containing herpes viruses as suggested and motivated by Kucera *et al.*

Claims 7-8 are rejected under 35 U.S.C. 103(a) as being unpatentable over **Kucera *et al.*** as applied to claims 1, 9-13, and 65 above, and further in view of **Holmes *et al.*** (New England Journal of Medicine, 2003, vol. 348, no. 20, pages 1948-1951 (cited by Applicants in IDS filed 9/14/2007)).

Kucera *et al.* teach as discussed *supra* and is applied herein for the same teachings. Claim 7-8 differ from Kucera *et al.* in that the reference does not disclose the treatment of a corona virus (*e.g.*, SARS-CoV).

However, Kucera *et al.* suggest and motivate the treatment of any virus type, especially membrane-containing or envelope containing viruses, wherein they teach that the compounds of Formula (I) disclosed therein attach to the cell membrane and thus are particularly effective against infections caused by membrane-containing or envelope containing viruses (col. 9, lines 42-45). Holmes *et al.* is provided as evidence that it was known in the art at the time of the invention that SARS corona virus contain a viral envelope (page 1949, right column and figure on page 1949).

Accordingly, it would have been *prima facie* obvious at the time of the invention to treat a corona virus, particularly a SARS corona virus, using the methods of Kucera *et al.* The skilled artisan would have been imbued with at least a reasonable expectation of success because Kucera *et al.* teach that the methods of treating viral infections disclosed therein are “particularly effective against infections caused by membrane-containing or envelope containing viruses”.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAMES D. ANDERSON whose telephone number is (571)272-9038. The examiner can normally be reached on MON-FRI 9:00 am - 5:00 pm EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/James D Anderson/
Examiner, Art Unit 1614

/Ardin Marschel/
Supervisory Patent Examiner, Art Unit 1614